Skip to the lineages
Regenerative Medicine

What Is Umbilical Cord Blood Used for in Approved Stem Cell Treatments?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. What hematopoietic progenitor cells are
  2. Why banked cord blood is used in transplantation
  3. DUCORD as one licensed example
  4. Donor compatibility and the transplant setting
  5. Cord blood is not umbilical cord tissue
  6. The risk of stretching an approval to unrelated uses
  7. How to check approval status

Approved cord blood products are used for one main purpose: transplanting blood-forming stem cells into patients whose blood and immune systems need to be rebuilt, such as people with certain blood cancers or inherited blood, metabolic or immune disorders. FDA’s list of approved cellular products includes nine entries named as cord blood hematopoietic progenitor cell (HPC) products, each licensed for transplantation. None is approved for arthritis, joint pain or any orthopedic use. FDA states that cord blood products “are not approved for other uses.”

What hematopoietic progenitor cells are

FDA’s consumer page Cord Blood Banking: Information for Consumers explains that “Cord blood contains hematopoietic progenitor cells” and that these HPCs “are blood-forming stem cells.” It states that this type of stem cell is “routinely used to treat patients with cancers such as leukemia or lymphoma, and other disorders of the blood and immune systems.” Blood-forming stem cells are an example of the tissue-specific adult stem cells described in the difference between embryonic and adult stem cells: they make blood cells, not cartilage or tendon.

Why banked cord blood is used in transplantation

Cord blood is collected after birth and can be stored. The National Library of Medicine’s MedlinePlus page on cord blood testing and banking states that stem cells from cord blood “can be used to treat certain blood disorders, including leukemia, Hodgkin disease, and some types of anemia,” and also “certain inherited metabolic and immune system disorders.” FDA explains that cord blood can go to a public bank for use by anyone who needs it, or to a private bank for the child or close relatives. Cord blood stored for unrelated patients is regulated as a drug and biological product and must be licensed under a biologics license application or used under an investigational new drug application.

DUCORD as one licensed example

FDA’s product page for DUCORD, made by Duke University School of Medicine, gives the full indication. It describes DUCORD as “an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.” In plain terms: donated cord blood cells, given after preparatory treatment, to rebuild the blood and immune system.

DUCORD is one of several. FDA’s directory of approved cellular and gene therapy products, content current as of October 30, 2026, lists these nine entries as cord blood HPC products:

Product Manufacturer listed by FDA
ALLOCORD (HPC, Cord Blood) SSM Cardinal Glennon Children's Medical Center
CLEVECORD (HPC Cord Blood) Cleveland Cord Blood Center
Ducord, HPC Cord Blood Duke University School of Medicine
HEMACORD (HPC, cord blood) New York Blood Center
HPC, Cord Blood Clinimmune Labs, University of Colorado Cord Blood Bank
HPC, Cord Blood – MD Anderson Cord Blood Bank MD Anderson Cord Blood Bank
HPC, Cord Blood – LifeSouth LifeSouth Community Blood Centers, Inc.
HPC, Cord Blood – Bloodworks Bloodworks
REGENECYTE (HPC, Cord Blood) StemCyte, Inc.

Each product has its own approved indication, found on its FDA page and label.

Donor compatibility and the transplant setting

Cord blood transplants require matching. FDA explains that “Human leukocyte antigen (HLA) typing is used to match patients and donors for cord blood transplants,” and that a close match can reduce the risk that the patient’s immune cells attack the donor’s cells, or that the donor’s immune cells attack the patient’s body. It adds that there “is evidence that cord blood HPCs may not require as exact a match” as HPCs from bone marrow or blood. As DUCORD’s indication states, the transplant is given “in conjunction with an appropriate preparative regimen,” a different procedure from an office injection. The DUCORD page notes that the risk-benefit assessment depends on the patient’s disease, stage and risk factors, the graft, and other available treatments. Why donor cells raise immune questions is covered in the risks of immune reactions to donor-derived cell products.

Cord blood is not umbilical cord tissue

Cord blood is the blood in the umbilical cord and placenta. Products made from the cord’s connective tissue, such as Wharton’s jelly, are different materials. FDA’s patient and consumer information on regenerative medicine therapies lists “umbilical cord blood and/or cord blood stem cells” and “Wharton’s jelly” separately among unapproved products that FDA says are marketed for “a wide range of diseases or medical conditions.” Wharton’s jelly is covered in what Wharton’s jelly is and why it is marketed for joint injections.

The risk of stretching an approval to unrelated uses

A clinic may point to cord blood’s approved status to suggest that a “cord-derived” joint injection is legitimate. The same FDA notice answers this directly in its note on cord blood: the products “are approved for use in patients with disorders that affect the production of blood,” but “they are not approved for other uses.” It also states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition, such as osteoarthritis.” An approval for transplant does not carry over to a knee.

How to check approval status

Ask for the exact product name and manufacturer, then look for it in FDA’s directory of approved cellular and gene therapy products and read its indication. A product that is not on the list, or whose indication is a blood disorder, is not approved for joint use. FDA’s cord blood page also notes that registration of a cord blood bank with FDA is a separate question from approval. The general steps are in how you can tell whether a regenerative medicine product is FDA-approved.

Approved cord blood products are blood-forming stem cell transplants licensed to rebuild the blood and immune system in specific disorders, and FDA states they are not approved for other uses, so cord blood approval provides no support for a cord-derived joint injection.

Cells linked to this one

This guide leads on to

Lineage E: Stem Cell Sources and Products

1 reader remark

Add a remark

Your email address will not be published. Required fields are marked *